Shopping Cart 0
Cart Subtotal
USD 0

A. Menarini Industrie Farmaceutiche Riunite Srl - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

A. Menarini Industrie Farmaceutiche Riunite Srl (Menarini), formerly Farmacia Internazionale, is a biopharmaceutical company that undertakes the research, development and manufacture of several pharmaceutical products in various dosage forms. The company's products portfolio is focused on a several therapeutic and wellness areas including allergy, andrology, antinfective areas, cardiovascular areas, gastrointestinal disorders, gynecology and women's wellness, respiratory areas, rheumatology, osteoporosis, dermatology and personal care, energy supplements and multivitamins, and others. Menarini operates through its manufacturing sites, research and development centers and has presence across Europe and Asia, Africa, Central and South America. It distributes products across several countries worldwide through partners and distributors. Menarini is headquartered in Florence, Italy.

A. Menarini Industrie Farmaceutiche Riunite Srl-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2012 to YTD 2018 10

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Menarini Raunaq Pharma Plans To Acquire Pharma Brands In India For USD 80 Million 14

Partnerships 15

Melinta Therapeutics Enters into Agreement with Menarini 15

Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 16

Menarini Asia-Pacific Enters into Agreement with Merck 17

Menarini Forms Joint Venture with BiosYnth 18

Moberg Extends Distribution Agreement with Menarini for Emtrix 19

Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 20

Moberg Pharma Extends Distribution Agreement With Menarini 21

Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 22

Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 23

Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 24

Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 25

Licensing Agreements 26

Menarini Enters into Licensing Agreement with Melinta Therapeutics 26

Menarini Enters into Licensing Agreement with Daiichi Sankyo 27

Berlin-Chemie Enters into Licensing Agreement with Selvita 28

Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 29

Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 30

Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 31

Vivus Enters Into Licensing Agreement With Menarini For Spedra 32

Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 34

A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 35

Sinclair IS Pharma Enters Into Licensing Agreement With Menarini Group For Three Products 36

FAES Farma Enters into License Agreement with Menarini For Bilastina 37

Almirall Enters Into Licensing Agreement With Invida For Aclidinium 38

Faes Farma And Invida Enter Into Licensing Agreement For Bilastine 40

Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 41

Acquisition 42

Menarini Group Plans To Acquire Indian Pharma Company 42

A. Menarini Industrie Farmaceutiche Riunite Srl-Key Competitors 43

A. Menarini Industrie Farmaceutiche Riunite Srl-Key Employees 44

A. Menarini Industrie Farmaceutiche Riunite Srl-Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Joint Venture 48

Recent Developments 49

Strategy And Business Planning 49

Mar 13, 2017: Menarini Arrives In Columbia And Peru Two New Offices For A Stronger Connection Between Two Continents 49

Jan 18, 2017: Menarini In Turkey: +25% Growth In 2016 And New Headquarters In Istanbul 50

Corporate Communications 51

Jun 29, 2017: Menarini Increases Number of Members of the Board-for the First Time External Members In Majority 51

Product News 52

Apr 12, 2017: Menarini Brings Sirmione Thermal Water Into Italian Homes 52

03/17/2017: Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia 53

Appendix 54

Methodology 54

About GlobalData 54

Contact Us 54

Disclaimer 54


List Of Figure

List of Figures

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Key Facts, 2017 2

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

A. Menarini Industrie Farmaceutiche Riunite Srl, Deals By Therapy Area, 2012 to YTD 2018 9

A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2012 to YTD 2018 10

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Menarini Raunaq Pharma Plans To Acquire Pharma Brands In India For USD 80 Million 14

Melinta Therapeutics Enters into Agreement with Menarini 15

Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 16

Menarini Asia-Pacific Enters into Agreement with Merck 17

Menarini Forms Joint Venture with BiosYnth 18

Moberg Extends Distribution Agreement with Menarini for Emtrix 19

Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 20

Moberg Pharma Extends Distribution Agreement With Menarini 21

Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 22

Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 23

Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 24

Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 25

Menarini Enters into Licensing Agreement with Melinta Therapeutics 26

Menarini Enters into Licensing Agreement with Daiichi Sankyo 27

Berlin-Chemie Enters into Licensing Agreement with Selvita 28

Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 29

Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 30

Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 31

Vivus Enters Into Licensing Agreement With Menarini For Spedra 32

Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 34

A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 35

Sinclair IS Pharma Enters Into Licensing Agreement With Menarini Group For Three Products 36

FAES Farma Enters into License Agreement with Menarini For Bilastina 37

Almirall Enters Into Licensing Agreement With Invida For Aclidinium 38

Faes Farma And Invida Enter Into Licensing Agreement For Bilastine 40

Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 41

Menarini Group Plans To Acquire Indian Pharma Company 42

A. Menarini Industrie Farmaceutiche Riunite Srl, Key Competitors 43

A. Menarini Industrie Farmaceutiche Riunite Srl, Key Employees 44

A. Menarini Industrie Farmaceutiche Riunite Srl, Subsidiaries 45

A. Menarini Industrie Farmaceutiche Riunite Srl, Joint Venture 48

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

A. Menarini Industrie Farmaceutiche Riunite Srl (Menarini), formerly Farmacia Internazionale, is a biopharmaceutical company that undertakes the research, development and manufacture of several pharmaceutical products in various dosage forms. The company's products portfolio is focused on a several therapeutic and wellness areas including allergy, andrology, antinfective areas, cardiovascular areas, gastrointestinal disorders, gynecology and women's wellness, respiratory areas, rheumatology, osteoporosis, dermatology and personal care, energy supplements and multivitamins, and others. Menarini operates through its manufacturing sites, research and development centers and has presence across Europe and Asia, Africa, Central and South America. It distributes products across several countries worldwide through partners and distributors. Menarini is headquartered in Florence, Italy.

A. Menarini Industrie Farmaceutiche Riunite Srl-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2012 to YTD 2018 10

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Menarini Raunaq Pharma Plans To Acquire Pharma Brands In India For USD 80 Million 14

Partnerships 15

Melinta Therapeutics Enters into Agreement with Menarini 15

Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 16

Menarini Asia-Pacific Enters into Agreement with Merck 17

Menarini Forms Joint Venture with BiosYnth 18

Moberg Extends Distribution Agreement with Menarini for Emtrix 19

Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 20

Moberg Pharma Extends Distribution Agreement With Menarini 21

Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 22

Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 23

Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 24

Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 25

Licensing Agreements 26

Menarini Enters into Licensing Agreement with Melinta Therapeutics 26

Menarini Enters into Licensing Agreement with Daiichi Sankyo 27

Berlin-Chemie Enters into Licensing Agreement with Selvita 28

Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 29

Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 30

Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 31

Vivus Enters Into Licensing Agreement With Menarini For Spedra 32

Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 34

A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 35

Sinclair IS Pharma Enters Into Licensing Agreement With Menarini Group For Three Products 36

FAES Farma Enters into License Agreement with Menarini For Bilastina 37

Almirall Enters Into Licensing Agreement With Invida For Aclidinium 38

Faes Farma And Invida Enter Into Licensing Agreement For Bilastine 40

Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 41

Acquisition 42

Menarini Group Plans To Acquire Indian Pharma Company 42

A. Menarini Industrie Farmaceutiche Riunite Srl-Key Competitors 43

A. Menarini Industrie Farmaceutiche Riunite Srl-Key Employees 44

A. Menarini Industrie Farmaceutiche Riunite Srl-Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Joint Venture 48

Recent Developments 49

Strategy And Business Planning 49

Mar 13, 2017: Menarini Arrives In Columbia And Peru Two New Offices For A Stronger Connection Between Two Continents 49

Jan 18, 2017: Menarini In Turkey: +25% Growth In 2016 And New Headquarters In Istanbul 50

Corporate Communications 51

Jun 29, 2017: Menarini Increases Number of Members of the Board-for the First Time External Members In Majority 51

Product News 52

Apr 12, 2017: Menarini Brings Sirmione Thermal Water Into Italian Homes 52

03/17/2017: Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia 53

Appendix 54

Methodology 54

About GlobalData 54

Contact Us 54

Disclaimer 54


List Of Figure

List of Figures

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Key Facts, 2017 2

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

A. Menarini Industrie Farmaceutiche Riunite Srl, Deals By Therapy Area, 2012 to YTD 2018 9

A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2012 to YTD 2018 10

A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Menarini Raunaq Pharma Plans To Acquire Pharma Brands In India For USD 80 Million 14

Melinta Therapeutics Enters into Agreement with Menarini 15

Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 16

Menarini Asia-Pacific Enters into Agreement with Merck 17

Menarini Forms Joint Venture with BiosYnth 18

Moberg Extends Distribution Agreement with Menarini for Emtrix 19

Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 20

Moberg Pharma Extends Distribution Agreement With Menarini 21

Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 22

Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 23

Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 24

Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 25

Menarini Enters into Licensing Agreement with Melinta Therapeutics 26

Menarini Enters into Licensing Agreement with Daiichi Sankyo 27

Berlin-Chemie Enters into Licensing Agreement with Selvita 28

Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 29

Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 30

Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 31

Vivus Enters Into Licensing Agreement With Menarini For Spedra 32

Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 34

A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 35

Sinclair IS Pharma Enters Into Licensing Agreement With Menarini Group For Three Products 36

FAES Farma Enters into License Agreement with Menarini For Bilastina 37

Almirall Enters Into Licensing Agreement With Invida For Aclidinium 38

Faes Farma And Invida Enter Into Licensing Agreement For Bilastine 40

Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 41

Menarini Group Plans To Acquire Indian Pharma Company 42

A. Menarini Industrie Farmaceutiche Riunite Srl, Key Competitors 43

A. Menarini Industrie Farmaceutiche Riunite Srl, Key Employees 44

A. Menarini Industrie Farmaceutiche Riunite Srl, Subsidiaries 45

A. Menarini Industrie Farmaceutiche Riunite Srl, Joint Venture 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS